Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology...

Area of Science:

• Oncology
• Drug Development
• Regulatory Science

Background:

• Project Optimus is an initiative by the US Food and Drug Administration Oncology Center of Excellence.
• It aims to reform the dose selection and optimization paradigm in oncology drug development.
• It brings together pharmaceutical companies, regulatory agencies, academic institutions, and patient advocates.

Purpose of the Study:

• To address challenges in oncology dose optimization, including multidimensionality, cancer/patient heterogeneity, long-term tolerability, and biomarker limitations.
• To offer insights into dose optimization using a Totality of Evidence approach and model-informed drug development.
• To build a quantitative knowledge base integrating diverse data sources for evidence-based drug dosage.

Main Methods:

• Leveraging quantitative modeling tools to integrate diverse data sources.
• Considering exposure, disease biology, efficacy, toxicity, and patient factors in dose optimization.
• Utilizing a Totality of Evidence approach and model-informed drug development principles.

Main Results:

• Development of a quantitative knowledge base for oncology drug dosage.
• Insights into optimizing drug dosage by considering multiple factors.
• A framework for rational dose optimization in oncology drug development.

Conclusions:

• Rational dose optimization is achievable in oncology drug development.
• Optimized dosing can improve patient outcomes by maximizing therapeutic benefit and minimizing toxicity.
• Project Optimus provides a pathway towards more effective and safer cancer therapies.